By K. John Morrow, Jr. Ph.D.
In the last two decades, the bioprocessing industry has confronted the demands of more rapid and efficient antibody purification as the number of antibody therapeutics in development continues to increase. The ever-increasing antibody titer concentrations creates a manufacturing bottleneck if downstream technologies are unable to advance rapidly enough to meet these demands. The increases on the upstream side are constantly pressuring those working in downstream to eliminate these bottlenecks and improve productivity and manufacturing efficiencies. As such, the appeal of pretested, disposable technologies holds great promise for the simplification of the production process.
Single-use technology has gained popularity for a variety of reasons, including flexibility, cost savings, and reliability. With many early-stage clinical trials underway, pharma and biotech companies are outsourcing development to CMOs in order to delay capital investment. This spurs a demand for development of multiple drug products produced at a single site.